Business
Willow Bioscience eyes another use for BioOxi platform with R&D of ursodeoxycholic acid
(NewsDirect) Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to...
About this update from Atlas Energy Corp.
[{"type":"text","content":"Willow Bioscience eyes another use for BioOxi platform with R&D of ursodeoxycholic acid\n \n \n (NewsDirect)\n \n \n \n \n Willow Bioscience CEO Dr Chris Savile\njoined Steve Darling from Proactive to announce some significant\ndevelopments within the company.\n \n \n Willow Bioscience specializes in the production of\nursodeoxycholic acid (UDCA), a vital pharmaceutical ingredient with\nextensive applications in nutraceutical and pharmaceutical products.\nUDCA is notably used in the management and treatment of cholestatic\nliver diseases and gallstone conditions. Moreover, it serves as a\ncrucial intermediate compound for tauroursodeoxycholic acid (TUDCA),\nan essential active pharmaceutical ingredient in a recently approved\ncombination therapy for the treatment of ALS in Canada and the United\nStates.\n \n \n In partnership with\nSandhill One, LLC, Willow has successfully completed research and\ndevelopment on its UDCA program. This collaborative initiative enabled\nWillow to optimize a proprietary enzyme necessary for UDCA\ndevelopment. Of particular significance is the achievement of\nselective C-H hydroxylation at an industrial scale, often regarded as\na challenging feat in the field of chemistry.\n \n \n Dr Savile's announcement also\nextended to the financial front. Willow Bioscience is initiating an\noffering of convertible debenture units in a non-brokered private\nplacement to raise approximately $1.2 million. Notably, insiders,\nincluding members of the Board of Directors and senior management, are\nexpected to subscribe to approximately 50% of the total funds raised.\nThis underscores the strong commitment and confidence that the\ncompany's leadership has in Willow's vision and future\nprospects.\n \n \n These developments indicate that Willow Bioscience\nis making significant strides in its mission to advance pharmaceutical\nresearch and contribute to the development of innovative therapies and\ntreatment options. With a focus on expanding its product portfolio and\nsecuring essential funding, the company is poised to play a pivotal\nrole in the pharmaceutical and nutraceutical industries.\n \n \n \n Contact Details\n \n \n \n Proactive Investors\n \n \n +1\n604-688-8158\n \n \n \n [email protected]\n \n \n \n Copyright (c) 2023 TheNewswire - All rights reserved.\n \n \n","length":2751,"tagName":"...